@article{article, title  = {{Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747).}},

 publisher = {{American Society of Clinical Oncology (ASCO)}},

 url = {{}},

 year = {{2013}},

 month = {{6}},

 author = {{James ND and Pirrie S and Barton D and Brown JE and Billingham L and Collins SI and Daunton A and Birtle AJ and Chakraborti PR and Ford D and Hussain SA et al}},

 doi = {{10.1200/jco.2013.31.18_suppl.lba5000}},

 volume = {{31}},

 journal = {{Journal of Clinical Oncology}},

 issue = {{18_suppl}},

 pages = {{LBA5000-LBA5000}},

 note = {{Accessed on 2024/12/21}}}